Qiagen Developing Next-Gen Molecular Tests To Capitalize on Untapped HPV Test Market | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
In the wake of its $1.6 billion acquisition of Digene, Qiagen CEO Peer Schatz said this week that the firm is working on a next-generation human papillomavirus molecular test to complement the one it already sells as well as an HPV test developed specifically for emerging markets.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.